Considerations in the Care of Non–Small-Cell Lung Cancer: The Value Imperative

摘要: Cancer costs in the United States continue to escalate at an alarming and unsustainable rate. These are not driven exclusively by a higher demand for services or aging population; rather, number of systemic failures, highlighted Institute Medicine (IOM), plague our cancer care delivery systems need be rectified. Drug costs, plus expensive diagnostic tests, hospital admissions/readmissions, unreasonable end-of-life care, combine inflate total cost care. Cancer, particularly lung cancer, is one most diseases States. While individual oncologists unlikely influence short term, they can become more proficient evaluating value derived from new treatment options maximizing clinical benefit their patients. Discussions patient values hinder patient-physician relationships, and, fact, strengthen them. This article discusses ways which oncologist incorporate into management patients with comply underlying principles Choose Wisely Campaign, as well recent American Society Clinical Oncology European Medical initiatives, bend curve downwards while maintaining efficacy.